Difelikefalin

What is Difelikefalin?

Difelikefalin is a synthetic D-amino acid tetrapeptide that selectively activates peripheral kappa opioid receptors without crossing the blood-brain barrier. It is FDA-approved as Korsuva for moderate-to-severe pruritus (itching) in adults with chronic kidney disease on hemodialysis. Its peripheral selectivity avoids the dysphoria and CNS effects of traditional kappa agonists.

What Difelikefalin Is Investigated For

Difelikefalin has one FDA-approved indication — moderate-to-severe pruritus in adults on hemodialysis — and is the first systemic therapy specifically approved for CKD-associated itch. The strongest evidence is the KALM-1 and KALM-2 Phase 3 trials, which enrolled hemodialysis patients with moderate-to-severe pruritus and demonstrated significant reductions in WI-NRS scores and quality-of-life improvements at week 12, with sustained benefit in the open-label extensions. A 2026 Phase 3 trial extended these findings to Chinese hemodialysis patients with comparable WI-NRS improvement, broadening the population evidence base beyond the predominantly Western KALM cohorts. The broader concept of peripheral kappa-opioid agonism as a novel pain and itch mechanism without CNS side effects or addiction liability is mechanistically interesting and supported by dedicated abuse-liability and respiratory-depression studies, but approved use is narrow — investigational work in non-dialysis CKD pruritus, notalgia paresthetica, and other pruritic conditions is ongoing but not yet approved. The honest caveat is that Korsuva is exclusively administered via the dialysis circuit by healthcare staff, cannot be self-administered, and has not demonstrated general analgesic efficacy despite earlier development attempts in postoperative pain.

History & Discovery

Difelikefalin (originally CR845) emerged from the targeted drug-discovery effort to develop kappa opioid receptor agonists with reduced central nervous system side effects — a long-standing pharmacological challenge given that traditional kappa opioids produce dysphoria, sedation, and hallucination through CNS-localized receptor activation. Cara Therapeutics, founded in 2004 specifically to advance peripheral opioid pharmacology, designed difelikefalin as a synthetic D-amino acid tetrapeptide whose hydrophilicity and molecular characteristics prevent meaningful blood-brain barrier penetration. The all-D-amino-acid composition also confers protease resistance, supporting parenteral pharmacokinetic stability. Early clinical development explored multiple indications including postoperative pain, but the program crystallized around chronic kidney disease-associated pruritus — a condition affecting roughly 40% of dialysis patients with substantially worse quality of life, sleep disruption, and mortality association. The pivotal Phase 3 KALM-1 (US/Canada/Europe, published in NEJM 2020) and KALM-2 (international) trials enrolled hemodialysis patients with moderate-to-severe pruritus and demonstrated significant reductions in itch intensity (primary endpoint: WI-NRS score) and improvements in itch-related quality of life. The intravenous formulation (Korsuva) received FDA approval in August 2021 for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis — the first FDA-approved systemic therapy specifically for this indication. In 2022, the EU approved Kapruvia (the same molecule under a different brand name through partnership with Vifor Pharma). Cara Therapeutics has continued investigation of an oral difelikefalin formulation for non-dialysis CKD pruritus, atopic dermatitis-associated pruritus, notalgia paresthetica, and other pruritic conditions, though the IV formulation in dialysis remains the principal approved use. The peripheral kappa-agonist concept is mechanistically novel within the modern analgesic and anti-pruritic armamentarium, and difelikefalin's success has stimulated broader investigation of peripheral opioid receptor pharmacology.

How It Works

Difelikefalin activates itch-relief receptors on nerve endings outside the brain. Because it can't enter the brain, it provides relief without the mood changes, sedation, or addiction risk of traditional opioid drugs.

Difelikefalin is a peripherally restricted kappa opioid receptor (KOR) agonist. D-amino acid composition prevents BBB penetration and confers protease resistance. Peripheral KOR activation on sensory neurons and immune cells modulates itch signaling and inflammation. KOR activation inhibits TRPV1 and substance P release from peripheral nerve terminals. The anti-pruritic effect is mediated through both neuronal and immunomodulatory mechanisms. A 2026 Nature Communications cryo-EM/rational-design study used difelikefalin's KOR-binding pose as the foundation for engineering attenuated β-arrestin recruitment, contextualizing difelikefalin as a structurally well-characterized reference KOR peptide agonist within the broader effort to dissociate analgesic/anti-pruritic efficacy from arrestin-driven side-effect signaling.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Difelikefalin:

• 01Non-dialysis CKD pruritus — oral difelikefalin investigation is ongoing for non-dialysis CKD patients but not yet approved; access for this population remains an unmet need.
• 02Peritoneal dialysis pruritus — KALM trials enrolled hemodialysis patients only; efficacy and dosing in peritoneal dialysis patients are not established.
• 03Other pruritic conditions — atopic dermatitis, notalgia paresthetica (Phase 2 data exists), cholestatic pruritus, and other indications are under investigation but lack approval. Early case-series exploration of off-label intravenous difelikefalin in refractory CKD-associated pruritus exists but is anecdotal and does not yet support broader use beyond the labeled dialysis indication.
• 04Long-term beyond-2-year safety — open-label extension data extends to roughly 2 years; longer-duration safety, including any cumulative cardiovascular or metabolic effects, requires ongoing pharmacovigilance.
• 05Mortality benefit signal — observational data suggests CKD pruritus is associated with worse mortality outcomes, raising the question of whether effective pruritus treatment translates to survival benefit; adequately powered mortality trials are not yet available.
• 06Mechanism of dizziness/somnolence despite peripheral restriction — clinical signal is real but mechanism (residual CNS exposure, peripheral-vagal autonomic effects, or other) is incompletely characterized.
• 07Beyond-pruritus indications for peripheral KOR agonism — preclinical signals such as the 2026 sepsis-associated acute kidney injury model raise the possibility of organ-protective applications, but these are early-stage and have not entered controlled human evaluation.

Forms & Administration

IV injection administered after hemodialysis sessions (0.5mcg/kg). Given by healthcare professionals 3 times per week.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Korsuva is FDA-approved only for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Use in non-dialysis CKD pruritus, peritoneal dialysis pruritus, or other pruritic conditions is not approved and is investigational. The IV formulation requires dialysis-circuit administration and is not appropriate for outpatient or non-dialysis settings.

Timeline of Effects

Common Questions

Who Difelikefalin Is NOT For

Drug & Supplement Interactions

Difelikefalin has a relatively limited drug-interaction profile due to its peptide proteolytic clearance (no significant CYP-mediated metabolism) and peripheral restriction. Central nervous system depressants (opioids, benzodiazepines, sedating antihistamines, anticonvulsants, alcohol): although difelikefalin itself has minimal CNS penetration, the dizziness and somnolence signals observed in clinical trials may be additive with concurrent CNS depressants. Patients on chronic opioid therapy in particular should be monitored carefully, especially during initiation; the co-administration analyses from KALM-1 and KALM-2 inform clinical decision-making. Kappa opioid antagonists (naltrexone, naloxone): theoretically could attenuate difelikefalin's anti-pruritic effect, though peripheral-restriction-specific data is limited. Clinical relevance is modest given naltrexone's primary indications. Medications that affect serum potassium (ACE inhibitors, ARBs, potassium-sparing diuretics, potassium supplementation, certain antibiotics): should be monitored given the trial hyperkalemia signal, though many dialysis patients are already on these agents and integrated potassium management is standard. As a peptide cleared partly by dialysis itself, dose timing relative to dialysis is built into the labeled administration (end of session). No formal dose adjustment for hepatic or renal function beyond dialysis context is required. As with any chronic specialty therapy in dialysis patients, all medications including OTC supplements should be disclosed to the dialysis care team.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions